Jazz Pharmaceuticals PLC.
JAZZ
$9.65 (3.83%)
1D
1W
3M
1Y
5Y
ALL
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 2 hours ago • JAZZ
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View
Seeking Alpha • 1 day ago • JAZZ
Jazz Pharmaceuticals plc (JAZZ) Q2 2026 Earnings Call Transcript
Zacks Investment Research • 1 day ago • JAZZ
Compared to Estimates, Jazz (JAZZ) Q2 Earnings: A Look at Key Metrics
Zacks Investment Research • 1 day ago • JAZZ
Jazz Pharmaceuticals (JAZZ) Q2 Earnings Lag Estimates
MarketBeat • 1 day ago • JAZZ
Jazz Pharmaceuticals Q2 Earnings Call Highlights
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.